Table 3. 6-monthly fracture rates per 100 patients at a median follow-up of 37 months in the ATAC trial (Howell, 2003; Locker and Eastell, 2003).

	6-monthly fracture rates/100 patients
Time (months)	Anastrozole (n=3092)	Tamoxifen (n=3093)	Anastrozole/tamoxifen 6-month hazard ratio
6	1.11	0.99	1.14
12	0.93	0.58	1.61
18	1.36	0.69	1.98
24	1.57	0.61	2.57
30	1.39	0.96	1.45
36	1.09	0.66	1.66
42	1.50	1.37	1.09
48	1.07	0.80	1.34

ATAC trial=Arimidex, Tamoxifen Alone or in Combination trial.